MapLight Therapeutics, Inc. (MPLT)
NASDAQ:MPLT
Top Page
MapLight Therapeutics, Inc.
(NASDAQ:MPLT)
Select Model
Select Model
Rating:56Neutral
Price Target:
$28.00
▲(60.09% Upside)
Action:ReiteratedDate:04/11/26
The score is held back primarily by persistent pre-revenue losses and worsening cash burn, which increases future financing risk. Offsetting this are a strong, lightly levered balance sheet and a positive corporate update indicating runway into 2027 with meaningful clinical catalysts ahead. Technically, the trend is strong but currently very overbought, limiting the near-term technical score, and valuation support is limited due to negative earnings and no dividend.
Positive Factors
Strong balance sheet / low leverage
Very low financial leverage and sizable equity provide durable financial flexibility for a clinical-stage biotech. This reduces near-term refinancing pressure, allows continued investment in trials, and gives management optionality to fund programs without immediate debt reliance, supporting multi-year development plans.
Negative Factors
Persistent pre-revenue losses
Being pre-revenue with materially widening net losses creates a durable structural weakness: the company must rely on external capital until commercialization. Growing losses increase the magnitude and frequency of financing needs, diluting shareholders and forcing trade-offs between program funding and balance sheet preservation.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet / low leverage
Very low financial leverage and sizable equity provide durable financial flexibility for a clinical-stage biotech. This reduces near-term refinancing pressure, allows continued investment in trials, and gives management optionality to fund programs without immediate debt reliance, supporting multi-year development plans.
Read all positive factors
MapLight Therapeutics, Inc. (MPLT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.12B
Dividend YieldN/A
Average Volume (3M)401.63K
Price to Earnings (P/E)―
Beta (1Y)2.00
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees109
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding42,436,325
10 Day Avg. Volume205,334
30 Day Avg. Volume401,626
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.58
Enterprise Value/Market Cap-0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit33.91
Enterprise Value/Ebitda0.12
Forecast
1Y Price Target
$36.00Price Target Upside105.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-4.04
Revenue Forecast (FY)N/A
MapLight Therapeutics, Inc. Business Overview & Revenue Model
Company Description
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscar...
How the Company Makes Money
null...
MapLight Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -578.00K | -701.00K | -556.00K | -574.00K |
| EBITDA | -168.50M | -76.88M | -55.15M | -29.44M |
| Net Income | -161.15M | -77.58M | -55.71M | -30.02M |
Balance Sheet | ||||
| Total Assets | 479.51M | 136.92M | 91.41M | 39.39M |
| Cash, Cash Equivalents and Short-Term Investments | 305.10M | 108.80M | 79.77M | 27.66M |
| Total Debt | 5.80M | 6.58M | 5.92M | 6.27M |
| Total Liabilities | 21.14M | 21.72M | 20.13M | 18.52M |
| Stockholders Equity | 458.37M | 115.19M | 71.28M | 20.87M |
Cash Flow | ||||
| Free Cash Flow | -138.61M | -79.58M | -52.47M | -27.32M |
| Operating Cash Flow | -138.14M | -78.81M | -52.01M | -26.58M |
| Investing Cash Flow | -323.21M | -80.79M | -462.00K | -746.00K |
| Financing Cash Flow | 469.82M | 118.06M | 104.57M | 33.17M |
MapLight Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $1.12B | -4.80 | -75.96% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $40.41M | -0.71 | -80.00% | ― | ― | 9.63% | |
44 Neutral | $2.05M | -0.20 | ― | ― | 178.82% | -4121.10% | |
44 Neutral | $5.23M | -0.28 | -203.36% | ― | ― | 90.53% | |
43 Neutral | $3.47M | -0.15 | -381.74% | ― | ― | 98.22% | |
43 Neutral | $3.45M | -0.14 | -215.04% | ― | -100.00% | 93.82% |
* Healthcare Sector Average
MPLT
MapLight Therapeutics, Inc.
27.02
8.68
47.33%
SCNI
Scinai Immunotherapeutics
0.59
-1.33
-69.22%
SNSE
Sensei Biotherapeutics
28.70
19.54
213.32%
GRI
GRI Bio
2.44
-41.52
-94.45%
DRMA
Dermata Therapeutics
1.25
-6.54
-83.95%
AZTR
Azitra Inc
0.22
-1.73
-88.89%
MapLight Therapeutics, Inc. Corporate Events
Business Operations and StrategyFinancial Disclosures
MapLight Therapeutics Highlights Growing CNS Pipeline, Strong Cash Position
Positive
Mar 26, 2026
On March 26, 2026, MapLight Therapeutics reported fourth-quarter and full-year 2025 results, highlighting an expanding CNS pipeline and increased RD investment. The company is advancing ML-007C-MA for schizophrenia and Alzheimer’s disease ps...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.